Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B

European Journal of Pharmacology
K T FinneganJ W Langston

Abstract

Clinical studies suggest that deprenyl may retard the progression of Parkinson's disease, an effect that may be related to its monoamine oxidase (MAO) inhibiting properties. Deprenyl also protects against the neurodegenerative effects of the noradrenergic toxin DSP-4. In this study we investigated the role of MAO B inhibition in this protection. C57BL/6 mice were given DSP-4 (50 mg/kg i.p.) 1 h. 24 h or 4 days after the administration of deprenyl (10 mg/kg i.p.) or the selective MAO B inhibitor MDL 72974 (1.25 mg/kg), and then killed 1 week later for assay of hippocampal norepinephrine. The MAO B inhibiting effects of deprenyl or MDL 72974 were also determined after these same intervals of time. Deprenyl and MDL 72974 produced comparable degrees of enzyme inhibition 1 h (greater than 95%), 24 h (greater than 90%) or 4 days (greater than 70%) after their administration. Given 1 h before, deprenyl totally blocked the norepinephrine-depleting effects of DSP-4, but this protection declined sharply when 24 h or 4 days was allowed to elapse between deprenyl and DSP-4 administration. MDL 72974 failed to protect at any time point. In vitro, we detected no activity using DSP-4 as a substrate for MAO. These findings suggest that the abil...Continue Reading

References

Dec 1, 1978·British Journal of Clinical Pharmacology·G P ReynoldsG M Stern
Jan 1, 1978·Journal of Neural Transmission·J Knoll
Nov 16, 1989·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Sep 2, 1987·European Journal of Pharmacology·C J Gibson
Sep 19, 1985·Nature·S H Snyder, R J D'Amato
Oct 1, 1981·The Journal of Pharmacy and Pharmacology·G A Lyles, B A Callingham
Sep 28, 1984·Science·J W LangstonL S Forno
Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·J Knoll
Apr 30, 1984·Biochemical and Biophysical Research Communications·K ChibaN Castagnoli
Jul 1, 1980·Journal of Neurochemistry·H KinemuchiK Kamijo
Mar 1, 1952·British Journal of Pharmacology and Chemotherapy·A SPINKS, J H BURN

❮ Previous
Next ❯

Citations

Dec 1, 1996·Annals of Neurology·C W OlanowJ Godbold
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·K T Finnegan
Dec 1, 1994·General Pharmacology·P H Yu
Jan 1, 1995·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·J Knoll
Jun 5, 1992·European Journal of Pharmacology·M GerlachM B Youdim
Feb 3, 2000·Mechanisms of Ageing and Development·W Maruyama, M Naoi
Mar 1, 1997·Neuroscience and Biobehavioral Reviews·I A PatersonC Voll
Dec 31, 2003·Neurotoxicology·Kálmán Magyar, Béla Szende
Mar 23, 2000·Brain Research. Developmental Brain Research·L GrocL Bezin
Aug 8, 2001·Parkinsonism & Related Disorders·M Naoi, W Maruyama
Jul 2, 2008·Parkinsonism & Related Disorders·P FoleyP Riederer
Mar 1, 2006·Proceedings of the National Academy of Sciences of the United States of America·Makoto R HaraSolomon H Snyder
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·P Jenner
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·E H Heinonen, R Lammintausta
Apr 1, 1997·Acta Neurologica Scandinavica·V V MyllyläE H Heinonen
Jul 23, 2003·CNS Drugs·Silvia MandelMoussa B H Youdim
Sep 1, 1996·Neurochemical Research·M D BerryA A Boulton
Nov 5, 1997·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·T RagaieyW C Stewart
Dec 30, 2003·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Rinat TabakmanPhilip Lazarovici
Sep 10, 2013·Translational Neurodegeneration·Kay Cheong Teo, Shu-Leong Ho
Mar 23, 2006·Nature Reviews. Neuroscience·Moussa B H YoudimKeith F Tipton
Sep 11, 2012·American Journal of Therapeutics·Saleem K Al-NuaimiGlen B Baker
Jul 21, 2001·Annals of the New York Academy of Sciences·W MaruyamaM Naoi
Jun 23, 2000·Annals of the New York Academy of Sciences·R M WuC C Chiueh
Nov 17, 1994·Annals of the New York Academy of Sciences·R M WuC C Chiueh

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.